No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
www.sphchina.comNo one on the platform currently holds 601607.SS.
No tracked institution reports a position in 601607.SS as of their last filing.
No one on the platform has traded 601607.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.2% | 7.8% | 8.7% | — | — | — |
| Rev. Growth % | 3.0% | 8.1% | ||||
| Profit Margin % | 2.0% | 2.0% | 2.2% | |||
| Free Cash Flow Margin % | 1.3% | 1.0% | 1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $296.5B | +3.6% | $1.48 | $1.41–$1.55 | — | 3 |
| 2027 | $312.7B | +5.5% | $1.54 | $1.45–$1.63 | — | 4 |
| 2028 | $333.7B | +6.7% | $1.65 | $1.53–$1.74 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | $0.65 | $0.57 | -12.1% |
| 2026-04-29 | $0.35 | $0.38 | +7.6% |
| 2026-03-31 | $0.20 | $0.16 | -17.9% |
| 2025-10-30 | $0.28 | $0.19 | -32.1% |
| 2025-08-25 | $0.83 | $0.84 | +1.2% |
| 2025-04-24 | $0.41 | $0.36 | -12.2% |
| 2025-03-26 | $0.21 | $0.14 | -33.3% |
| 2024-10-29 | $0.27 | $0.30 | +11.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 601607.SSShanghai Pharmaceuticals Holding Co., Ltd | $16.16 | -0.31% | $59.9B | — |
| 000963.SZHuadong Medicine Co., Ltd | $26.19 | -1.02% | $45.9B | — |
| 000999.SZChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | $24.05 | -0.29% | $40.0B | — |
| 002001.SZZhejiang NHU Company Ltd. | $26.68 | -0.26% | $82.0B | — |
| 002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd. |
| $29.51 |
| -0.30% |
| $32.9B |
| — |
| 002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A | $40.65 | -1.76% | $64.7B | — |
| 002653.SZHaisco Pharmaceutical Group Co., Ltd. | $63.30 | -0.30% | $70.9B | — |
Source: Financial Modeling Prep · peers by sector/industry